Trial to Evaluate Tibolone in the Treatment of Osteoporosis (P06468)
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
Tibolone 1.25 mg is an effective treatment for the prevention of osteoporosis and is expected
to be effective in preventing fractures in osteoporotic women. Tibolone could be more
acceptable for long-term use, in particular since it does not induce a regular withdrawal
bleed.
The objective of this trial is to compare placebo and tibolone, a steroid with tissue
specific activity, in the prevention of spinal fractures in women meeting the WHO criteria
for osteoporosis or who have asymptomatic vertebral fractures.